ResMed
RMD
731 hedge funds and large institutions have $20.8B invested in ResMed in 2023 Q2 according to their latest regulatory filings, with 95 funds opening new positions, 257 increasing their positions, 252 reducing their positions, and 37 closing their positions.
657% more call options, than puts
Call options by funds: $189M | Put options by funds: $24.9M
157% more first-time investments, than exits
New positions opened: 95 | Existing positions closed: 37
8% more funds holding
Funds holding: 676 → 731 (+55)
2% more repeat investments, than reductions
Existing positions increased: 257 | Existing positions reduced: 252
0.16% more ownership
Funds ownership: 64.74% → 64.9% (+0.16%)
1% less capital invested
Capital invested by funds: $21B → $20.8B (-$124M)
10% less funds holding in top 10
Funds holding in top 10: 10 → 9 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$141M |
| 2 |
Man Group
London,
United Kingdom
|
+$106M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$91.6M |
| 4 |
Jane Street
New York
|
+$69M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$64.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$422M |
| 2 |
BlackRock
New York
|
-$201M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$90.2M |
| 4 |
Amundi
Paris,
France
|
-$71.8M |
| 5 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$56.3M |
RMD Hedge Fund Activity: Q2 2023 in Review
731 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in ResMed (RMD) for Q2 2023, worth a combined $20.8B — down 0.59% from $21B a quarter earlier.
Buyers outnumbered sellers: 95 funds opened new RMD positions and 37 closed out — a net gain of 58 holders — while 257 added to existing stakes and 252 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $141M. The largest seller was Capital World Investors, cutting an estimated $422M.
- 731 institutional investors held ResMed (RMD) as of Q2 2023, up from 676 in Q1 2023.
- Funds reported $20.8B of ResMed stock for Q2 2023, down 0.59% quarter-over-quarter.
- 95 funds opened new ResMed positions in Q2 2023 and 37 closed out, a net change of +58 holders.
- The largest ResMed buyer in Q2 2023 was Millennium Management, an estimated $141M added.
- The largest ResMed seller in Q2 2023 was Capital World Investors, an estimated $422M sold.
Based on aggregated 13F filings for Q2 2023.